Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 116 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? April 27, 2021 How Music Can Help You Cope During Cancer: An Expert Perspective October 5, 2021 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 Load more HOT NEWS Community Surprises Teen Battling Bone Cancer With Brand New Car For... Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow Man Who Lost His Mother to Breast Cancer Opens Resource Center... Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with...
